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A B S T R A C T   
MicroRNA-1 (miR-1) is a conserved miRNA with high expression in the muscle tissues. In humans, two discrete 
genes, MIRN1-1 and MIRN1-2 residing on a genomic region on 18q11.2 produce a single mature miRNA which 
has 21 nucleotides. miR-1 has a regulatory role on a number of genes including heat shock protein 60 (HSP60), 
Kruppel-like factor 4 (KLF4) and Heart And Neural Crest Derivatives Expressed 2 (HAND2). miR-1 has critical 
roles in the physiological processes in the smooth and skeletal muscles as well as other tissues, thus being 
involved in the pathogenesis of a wide range of disorders. Moreover, dysregulation of miR-1 has been noted in 
diverse types of cancers including gastric, colorectal, breast, prostate and lung cancer. In the current review, we 
provide the summary of the data regarding the role of this miRNA in the normal development and the pathogenic 
processes.   
1. Introduction 
MicroRNA-1 (miR-1) is a conserved miRNA with high expression in 
the muscle tissues particularly the heart muscle and is involved in the 
development of this tissue [1,2]. Being encoded by a genomic region on 
18q11.2, the miR-1 subfamily comprises 2 discrete genes, MIRN1-1 and 
MIRN1-2 which code for the same mature miRNA which has 21 nucle-
otides [3]. It has a regulatory role on a number of genes such as heat 
shock protein 60 (HSP60) and Kruppel-like factor 4 (KLF4) at the post 
transcriptional level [4,5]. Moreover, Heart And Neural Crest De-
rivatives Expressed 2 (HAND2), a transcription factor (TF) that stimu-
lates ventricular cardiomyocyte development, has been identified to be 
targeted by miR-1 [3]. Meanwhile, miR-1 has been shown to be targeted 
by a number of muscle differentiation regulators, such as serum 
response factor, MyoD and MEF2 [3]. Investigations in animal models 
have revealed that miR-1 enhances myogenesis through modulating 
histone deacetylase-4, a suppressor of muscle gene expression [6]. In 
addition to its critical roles in the physiological processes in the smooth 
and skeletal muscles, it regulates several functions in other tissues, thus 
being involved in the pathogenesis of a wide range of disorders. In the 
current review, we summarize the data regarding the role of this miRNA 
in the normal development and the pathogenic processes. 
2. miR-1 in normal development 
Numerous studies have reported the role of miR-1 in developmental 
processes. Consistent with its role in the development of heart tissue, 
Trhriz et al. have reported over-expression of miR-1 in the course of 
cardiac differentiation of embryonic stem cells in mice. Cdk9 has been 
shown to mediate up-regulation of miR-1 to induce myoblast apoptosis 
[7]. Moreover, Dai et al. have shown the role of this miRNA the prolif-
erative ability and differentiation of skeletal muscle satellite cells. This 
miRNA has been shown to target the 3′UTR of Pax7 and HDAC4. This 
miRNA promotes bovine skeletal muscle satellite cell myogenic differ-
entiation inhibiting expression of these genes [8]. A significant portion 
of predicted miR-1 targets have been enriched in RNA metabolism. The 
* Corresponding authors. 
E-mail addresses: mohammad_823@yahoo.com (M. Taheri), S.ghafourifard@sbmu.ac.ir (S. Ghafouri-Fard).  
Contents lists available at ScienceDirect 
Biomedicine & Pharmacotherapy 
journal homepage: www.elsevier.com/locate/biopha 
https://doi.org/10.1016/j.biopha.2020.110903 
Received 9 September 2020; Received in revised form 13 October 2020; Accepted 14 October 2020   
Biomedicine & Pharmacotherapy 132 (2020) 110903
2
splicing factor Srsf9 has been recognized as another target of miR-1 
during myogenesis [9]. Nakamura et al. have used a microarray-based 
technique to assess miRNA expression during tooth development. 
They demonstrated a distinctive signature for miR-1 in the developing 
tooth. Expression of this miRNA in the tooth germ has been increased 
until embryonic day 16.5, then being reduced progressively on postnatal 
days 1 and 3. This miRNA has been shown to be present at the cervical 
ring of the dental epithelium. Connexin (Cx) 43 has been identified as a 
target of miR-1. Reduction of miR-1 level has decreased proliferation 
rate of cells but accelerated the rate of ATP release. Collectively, their 
investigations showed that miR-1 modulates expression of Cx43 to in-
fluence cell proliferation rate in the course of dental epithelial cell 
Fig. 1. Schematic illustration of the impact of miR-1 on PI3K/AKT/mTOR/NFκB Pathway.  
Table 1 
Summary of the results of studies that assess the functional roles of miR-1 during development of different tissues.  
Samples Cell Lines Target Pathway Function Ref 
GEO database SF2 CX43 – Expression of miR-1 was increased in the course of tooth development. miR-1 by 
modulating Cx43 could modulate cell proliferation during dental epithelial cell 
differentiation. 
[10] 
– C2C12, AB1 ES Cdk9, P53, P21, MyoD, 
Srf, Mef2 
– Cdk9 by modulation of miR-1 and myogenic transcription factors could regulate 




– Pax7, HDAC4, MHC – miR-1 via inhibiting the Pax7/HDAC4 axis could have a role in the proliferation 
and differentiation of skeletal muscle satellite cells. 
[8] 
Mouse C2C12 Srsf9 – miR-1 by targeting Srsf9 could promote C2C12 differentiation. [9] 
– NSCs Hes1, Nestin, Cyclin- 
D1, β-tubulin-III, GFAP 
UCA1 UCA1/miR-1 axis by targeting Hes1 could regulate neural stem cell 
differentiation. 
[16] 
Goat – HDAC4 – miR-1 by inhibiting HDAC4 in skeletal muscle satellite cells could promote 
muscle development. 
[17] 
– NHAs CCL2, GFAP, S100β, IL- 
6, TNF-α, Vimentin 
H19 H19/miR-1-3p/CCL2 axis might participate in modulating NHA activation and 
proliferation. 
[18] 
– 293 T, H1299, 
NB4, C2C7, 
NIH3T3, 
Zfp281, ZNF281 – miR-1 by targeting the ZNF281/Zfp281 axis could be involved in counteracting 
muscle differentiation. 
[19] 
– BMSCs TLR1, Runx2, OPN – Down-regulation of miR-1 by regulating the Runx2/OPN axis and inhibiting 
TLR1 could promote osteogenic restoration of bone marrow mesenchymal stem 
cells. 
[11] 
Duck – THBS1, Bcl-2, FAS aplacirc_013267 Aplacirc_013267 by sponging apla-miR-1-13 and regulating THBS1 could 




– Bdtra, TRA – During the embryonic developmental stages, miR-1-3p by suppressing Bdtra 
expression could induce male sex determination. 
[15]  
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differentiation [10]. Down-regulation of miR-1 expression in bone 
marrow mesenchymal stem cells (BMSCs) has led to attenuation of their 
proliferation, suppression of Caspase 3 activity, and over-expression of 
osteogenic genes Runx2 and OPN expression while down-regulation of 
TLR1 expression. TLR1 has been identified as a target of miR-1. miR-1 
silencing in BMSCs of fractured rats has enhanced bone density and ALP 
activity and increased expressions of type I collagen and BMP-2, indi-
cating the role of miR-1 silencing in enhancement of osteogenic differ-
entiation and bone healing [11]. This miRNA is also involved in 
mediation of the effects of a certain circular RNA (circRNA) on gran-
ulosa cells. The circRNA aplacirc_13267 enhances apoptosis of duck 
granulosa cell through the apla-miR-1-13/THBS1 axis [12]. In addition, 
miR-1 participate in the regulation of the autophagy process via mod-
ulation of a number of conserved Rab GTPase-activating proteins [13]. 
Notably, IFNB-mediated regulation of Mir1 and its effects on the 
reduction of TBC1D15, a RAB GTPase-activating protein possibly con-
tributes in the pathogenesis of Parkinson’s disease [14]. Finally, Peng 
et al. have shown the role of miR-1-3p in male sex determination in an 
Oriental fruit fly. This miRNA inhibits expression of Bdtra, a necessary 
factor in female sex determination [15]. Fig. 1 shows the influence of 
miR-1 on PI3K/AKT/mTOR/NFκB Pathway. 
Table 1 shows the outcomes of studies that assess the functional roles 
of miR-1 during development of different tissues. 
3. Up-regulation of miR-1 in disorders 
Consistent with diverse roles of miR-1, expression of this miRNA has 
been dysregulated in various disorders. Lv et al. have shown up- 
regulation of miR-1 in H2O2 exposed cardiomyocytes and in mice 
model of myocardial infarction (MI). This up-regulation was accompa-
nied by down-regulation of the potassium channel 2.1 (Kir2.1) and 
CX43, prolongation of the PR and QT intervals, delay in action potential 
period and decrease in conduction pace. Notably, metformin could 
amend these effects through suppressing miR-1 expression [21]. Li et al. 
have assessed levels of miR-1-3p in peripheral blood mononuclear cells, 
cerebrospinal fluid and different population of T cells obtained from 
healthy subjects and multiple sclerosis (MS) patients. They reported 
up-regulation of this miRNA in MS patients during relapse phase in 
Table 2 
Summary of studies which reported up-regulation of miR-1 in human/animal disorders.  
Type of Disease Samples Cell Lines Target Pathway Function Ref 
Myocardial Infarction 
(MI) 
Mouse NMVCs CX43, Kir2.1 – Metformin (200 mg/kg/d for 4 weeks) by 
regulating miR-1 could ameliorate 
cardiac conduction delay in mice. 
[21] 
Acute Myocardial Infarction 
(AMI) 
AMI (n = 44), normal 
controls (n = 18) 
– – – Changes in miR-1 levels in plasma could 
be used as diagnostic/prognostic 
indicators of adverse ventricular 
remodeling. 
[25] 
Viral Myocarditis Mouse HL-1 Cx43 – Astragalus root dry extract via regulating 
the miR-1/Cx43 axis could present strong 
cardioprotective effects on viral 
myocarditis. 
[26] 
Myocardial Steatosis Mouse/human; 
serum samples from 
uncomplicated type 2 
diabetes (n = 78) and 
normal control (n = 12) 
HL-1 – – Serum miR-1 could be used as a reflection 
of myocardial steatosis in uncomplicated 
type 2 diabetes. 
[27] 
Multiple Sclerosis (MS) MS (n = 36), healthy 
controls (n = 33) 
Th17, Th1, Th2, 
Treg 
ETS1, RORC, CSF2, 
AHR, IL-10, MAF, 
CXCL3, CSF2, IL-23R 
– Overexpression miR-1-3p by targeting 
ETS1 could affect the differentiating 
process of Th17 in MS patients. 
[22] 




4, MMP, ROS, NF-kB 
RMRP The lncRNA RMRP through the miR-1- 
5p/HSP70 route could prevent 
mitochondrial dysfunction and 





Rat – KCNA5 – miR-1 by targeting KCNA5 could reduce 
the activity and expression of Kv channels 
and also induce pulmonary artery smooth 
muscle cell hypertrophy. 
[28] 
PAH – PASMCs SOD1, GJA1, CAV2, 
KLF4 
– miR-1 by regulating endothelial genes 
could induce endothelial dysfunction in 




Non-left ventricular (LV) 
remodeling (n = 58), LV 
remodeling (n = 22) 
– – – miR-1 is increased in the remodeling 
group. Therefore, miR-1 could be 
involved as a predictive factor of LV 




with Interstitial Lung 
Disease (PM/DM-ILD) 
PM/DM (n = 22), healthy 
controls (HC) (n = 30), 
systemic lupus 
erythematosus (n = 11) 
– – – Increased miR-1 level in serum could be 
used as a marker for observing disease 
activity and forecasting treatment 
response in PM/DM. 
[31] 
Acute Chest Pain (ACP) AMI (n = 174), non-AMI 
(n = 176), non-ACP 
(n = 100) 
– – – The increased concentration of miR-1 in 
the AMI and non-AMI group relative to 
the non-APC group could be used as a 
diagnostic and prognostic method. 
[32] 
Non-Alcoholic Fatty Liver 
Disease (NAFLD) 
Mouse Huh7, 293 T, 
THP-1, HUVECs 
NF-kB, KLF4 – Hepatocyte-derived extracellular vesicles 
via the miR-1/KLF4/NF-kB pathway 
could promote endothelial inflammation 
and facilitate atherogenesis. 
[18] 
Cerebral Palsy (CP) Rat N2A BDNF, Caspase-3 MALAT1, 
PI3K/Akt 
Vitamin B1 and B12 by increasing BDNF 
via the MALAT1/miR-1 axis could 
contribute to alleviating neuron apoptosis 
and nerve damage in CP. 
[24]  
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correlation with MS severity. Up-regulation of this miRNA in naïve 
CD4+T cells enhanced differentiation of Th17 cells. miR-1-3p regulates 
differentiation Th17 cells through modulating expression of ETS1 [22]. 
Han et al. have shown the role of miR-1-5p in attenuation of the pro-
tective effect of HSPA4 against lipopolysaccharide-associated mito-
chondrial injury and apoptosis. The lncRNA RMRP axis has been shown 
to serve as a sponge for miR-1-5p. RMRP suppresses 
lipopolysaccharide-induced apoptosis of cardiomyocytes and mito-
chondrial injury through inhibiting the impact of miR-1-5p on HSPA4 
[23]. Jiang et al. have confirmed the role of this miRNA in liver steatosis. 
They observed that steatotic hepatocyte secrete miR-1-containing 
extracellular vesicles that enhance endothelial inflammation and 
induce atherogenesis through inhibition of KLF4 and induction of NF-κB 
[18]. Deprivation/reoxygenation reduces MALAT1 and BDNF levels and 
enhance the miR-1 levels. These effects have been ameliorated by 
vitamin B1 and B12 administration. These vitamins decreased miR-1 
expression through MALAT1, enhanced BDNF levels and induced 
PI3K/Akt pathway via the MALAT1/miR-1 axis, therefore precluding 
neuron apoptosis and modifying nerve damage in cerebral palsy rats 
[24]. Table 2 shows the outcomes of experiments which reported 
up-regulation of miR-1 in human/animal disorders. 
4. Down-regulation of miR-1 in disorders 
Contrary to studies which reported up-regulation of miR-1 in acute 
myocardial infarction (AMI) [21,25], Pinchi et al. have confirmed 
down-regulation of this miRNA in postmortem hearth samples of AMI 
patients compared with sudden cardiac death and controls [33]. Wu 
et al. have judged the effects of Wenxin Granules on prevention of fatal 
arrhythmia by modulating gap junctions and miR-1 after MI in a rat 
model constructed by coronary artery ligation. Wenxin Granules pre-
served the configuration of the gap junctions and their fundamental 
Cx43 levels by modulating miR-1 [34]. miR-1 has a vital role in the 
maintenance of cardiac rhythms [35] and its suppression may cause 
cardiac hypertrophy and arrhythmia [36]. Fig. 2 displays involvement of 
miR-1 in cardiac hypertrophy. 
Up-regulation of this miRNA prohibited T3 -associated car-
diomyocyte hypertrophy and decreased HADC4 expression in car-
diomyocytes. Expression of this miRNA has also been decreased in 
cardiac tissues of hyperthyroid animals [37]. miR-1 has also been 
down-regulated in persons with symptomatic heart failure in association 
with the severity of this condition. Expression level of this miRNA has 
been suggested as a biomarker for predicting heart failure exacerbation 
[38]. Besides, miR-1-3p has been shown to decrease expression SFRP1, 
thus enhancing bone formation and mass and counteracting with the 
pathogenesis of osteoporosis [39]. Expression of miR-1 has also been 
decreased after sciatic nerve damage, leading to over-expression of 
BDNF, and enhancement of proliferation and migration of Schwann 
cells. This finding might facilitate design of novel therapeutic modalities 
for management of peripheral nerve injury [40]. Table 3 reviews the 
results of studies which reported down-regulation of miR-1 in 
human/animal disorders. 
5. miR-1 expression in cancers 
The bulk of evidence points to the tumor suppressor role of this 
miRNA. Peng et al. have reported decreased levels of miR-1 in breast 
cancer cells. Over-expression of this miRNA has blocked cell 
Fig. 2. Schematic illustration of modulation of the TGF-β1 signaling pathway by miR-1. This miRNA targets TGF-βR1/ALK5 and inhibits the TGF-β signaling 
pathway, thus participating in cardiac hypertrophy. 
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proliferation, migration and invasion and stimulated cell apoptosis. The 
tumor suppressor effects of this miRNA have been exerted through tar-
geting Bcl-2. Notably, such inhibitory effects on tumor volume and 
weight have been verified in nude mice. Moreover, up-regulation of 
miR-1 has increased the toxic effects of paclitaxel and cisplatin on breast 
cancer cells [50]. Although miR-1 has been shown to be decreased in 
gastric cancer samples by independent investigations [51–53], Liu et al. 
have shown its up-regulation in serum specimens of patients with this 
kind of malignancy [54]. Loss of miR-1 has resulted in the 
over-expression of PD-L1 in sorafenib-resistant hepatoma cells. Mecha-
nistically, miR-1 has been shown to target PD-L1. Down-regulation of 
miR-1 in these cells has been attributed to over-expression of Nuclear 
factor E2-related factor 2 (NRF-2) [55]. Mutant ACTB mRNA 3′-UTR has 
been shown to be over-expressed in hepatocellular carcinoma (HCC) 
samples. This mutation facilitates its interaction with miR-1 and 
miR-29a and destruction of these miRNAs via AGO2, enhancing HCC 
cells migration and invasion by increasing expression of miR-1 target 
gene MET and miR-29a target gene MCL1 [56]. Wu et al. have reported 
down-regulation of miR-1 in colorectal cancer tissues and cell lines 
compared with neighboring non-cancerous tissues. Up-regulation of this 
miRNA has resulted in suppression of colony endurance and prolifera-
tion, and induction of apoptosis upon irradiation. This miRNA increases 
Bax and E-cadherin levels and down-regulates Bcl-2, MMP2 and MMP9 
expressions. Moreover, miR-1 has improved the sensitivity of cancer 
cells to radiotherapy [57]. In breast cancer cells, diverse studies have 
demonstrated various routes for contribution of miR-1 in the carcino-
genic process. For instance, miR-1 has been shown to defeat prolifera-
tion of cancer stem cells through modulation of EVI-1 [58]. In addition, 
miR-1 can inhibit evolution of triple-negative breast cancer through 
inhibition of Slug expression [59]. Finally, miR-1 modulates apoptotic 
processes, then sensitizing breast cancer cells to paclitaxel and cisplatin 
[50]. Besides, the role of some lncRNAs such as RMRP and MALAT1 in 
the pathogenesis of cancer is mediated through sponging miR-1 [60,61]. 
This miRNA has direct or indirect interactions with several 
cancer-related molecules such as VEGF, MET, c fos, c jun, BCL 2, Bax and 
Bcl-2, thereby influencing cancer course via different mechanisms. 
Table 3 
Outlines of studies which reported down-regulation of miR-1 in human/animal disorders.  
Type of Disease Samples Cell 
Lines 
Target Pathway Function Ref 
Myocardial Infarction (MI) Rat – PKC, CX43, Cx45, 44/ 
42 MAPK, ELK-1, SRF 
– Wenxin Granules (WXKL) by regulating miR-1 
and PKC can preserve the configuration of gap 




Serum samples from normal controls 
(n = 18), AMI (n = 19), Sudden 
Cardiac Death (n = 25) 
– CD15, IL-15, CX43, 
MCP-1, tryptase, 
troponin-C, troponin-I 
– A low level of miR-1 in serum specimens of AMI 
patients could be used as a marker for 




Rat NRCMs ANP, BNP, 
α-actin, HDAC4 
– Overexpression of miR-1 by reducing HDCA4 





Rat NRVCs CDK6, ANF, 
B-MHC 
CDKs-Rb miR-1 via down-regulating CDK6 and 
inactivating the Rb pathway could inhibit 
hypertrophic phenotype in cardiomyocytes. 
[41] 
Symptomatic Heart Failure 
(SHF) with Left 
Ventricular Hypertrophy 
(LVH) 
SHF (n = 59) and normal controls 
(n = 17) 
– – – miR-1 and galectin-3 level in SHF patients with 
LVH could be associated with anatomic 
alterations of the left ventricle. 
[42] 
SHF Blood sample from SHF (n = 61) – NT-proBNP – Down-regulation of miR-1 could be used as a 
biomarker for predicting HF exacerbation. 
[38] 
Acute HF with 
Asymptomatic Type 2 
Diabetic (DM) 
Serum samples from normal controls 
(n = 45), DM + coronary artery 
disease (CAD) (n = 45), HF + DM 
(n = 45), DM (n = 45) 
– NT-proBNP, Galectin- 
3 
– miR-1 could be useful in predicting the onset of 
HF in asymptomatic T2DM patients. 
[43] 
Osteoporosis (OS) Mouse/human; 
OS (n = 29), non-OS (n = 20) 






miR-1-3p by targeting SFRP1 could regulate the 





Ossification of the posterior 
longitudinal ligament (OPLL, = 52), 
non-OPLL (n = 16) 
– CX43, COL I, OCN, 
ALP, RUNX2, NF- 
kBp65, OCN, IL6, 
TNFα, BMP2  
MALAT1 MALAT1/miR-1 axis by targeting CX43 could 
mediate OPLL. 
[44] 
Osteoarthritis (OST) Mouse/human; 
20 pairs of OST and neighboring 
normal tissues 
– Ihh – miR-1 by down-regulating Ihh expression could 
protect the articular cartilage from 
osteoarthritis‑induced degeneration. 
[18] 
Viral Myocarditis (VMC) Mouse – Bax, Bcl-2, Caspase-9, 
Kcnd2, Irx5, Kcnj2, 
Kir2.1 
– miR-1 by modulating the expressions of 
apoptosis-associated genes could ameliorate 
cardiac function and reduce cardiomyocyte 








TGF-β miR-1 via targeting TGF-βR1 and reducing TGF- 
β signaling could be involved in the cardiac 
hypertrophy. 
[46] 
Keloid Keloid tissues (n = 11), normal skin 
(n = 8) 
HKFs, 
HSFs 
TM4SF1, Fibronectin AKT/ 
ERK 
miR-1-3p by targeting TM4SF1 via regulating 
AKT/ERK signaling could inhibit proliferation 
and migration in keloid. 
[47] 
Atrial Fibrillation (AF) Post-operative AF (POAF = 24) and 
non-OAF (n = 24) 
– – – A reduction of the miR-1 level in the AF could 
participate in the development of POAF. 
[48] 
Peripheral Nerve Injury Rat SC BDNF – miR-1 by targeting BDNF could regulate 
Schwann cell proliferation and migration after 






HSP-70, Bax, Cyt C, 
MMP, 
Caspase-3 
– miR-1 by targeting HSP-70 could have a role in 
hypoxia-induced apoptotic injury to neuro-2a 
cells via the intrinsic apoptotic pathway. 
[49]  
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Table 4 
Summary of studies which reported down-regulation of miR-1 in cancers (ANT: adjacent normal tissue).  
Type of Cancer Samples Cell Lines Target Pathway Function Ref 
Gastric Cancer (GC) – GES-1, HGC-27, 
SGC-7901, MGC-803, 
MKN-28 
MMP-7, VEGF, Sorcin, 
E-cadherin, 
N-cadherin 
– Overexpression of miR-1 by targeting 
the MMP-7/VEGF axis could inhibit the 
mobility and migration of GC cells. 
[51] 
GC 90 pairs of GC and ANTs GES-1, SGC7901, 
MKN28, AGS, NCIN87, 
BGC823, HGC27 
VEGFA, EDN1, MET – miR-1 by suppressing the expression of 
VEGF-A and EDN1 could inhibit 
proliferation, migration, and tube 
formation of endothelial cells. 
[52] 
GC 48 pairs of GC and ANTs AGS, SGC-7901 MET, Survivin – miR-1 by targeting MET could inhibit 
GC cell proliferation and migration. 
[53] 
GC – SGC7901/ADM, 
SGC7901/VCR, 
SGC7901 
Sorcin, c-fos, c-jun, BCL- 
2, Bax, Bcl-2, MDR1/P- 
gp, MRP-1 
– miR-1 by inhibiting sorcin via 
promoting the accumulation of 
intracellular drugs and apoptosis of 
cells could reverse multidrug resistance 
in GC cells. 
[62] 
GC 62 pairs of GC and ANTs GES-1, AGS, MGC803 STC2 – miR-1-3p by down-regulating STC2 




Mouse GES-1, AGS, MKN45, 
AZ521, 
HCT-116 
HDAC6, HNF4α, CDX2, 
MUC2, KLF4 
– miR-1 by mediating HDAC6/HNF4α 
loop could promote bile acids (BA)- 





(N = 10), normal cerebellar 
samples (n = 5) 
Daoy, D283 med, D341 YY1, E-cadherin, 
Vimentin, Fibronectin, 
α-SMA 
HOTAIR HOTAIR by sponging miR-1 and 
targeting YY1 could promote MDB 
growth, migration, and invasion. 
[65] 
Liver cancer Mouse Hep3B, HepG2, 
HepG2-SR, Hep3B-SR 
PD-L1, P-gp, MRP1 NRF-2 NRF-2/miR-1 axis by up-regulating PD- 
L1 could promote tumorigenic 
properties and enhance drug resistance 
in sorafenib-resistant hepatoma. 
[55] 
Breast Cancer (BCa) Mouse/human; 47 pairs of 
BCa and ANTs 
MCF-7, 
ZR-7530 
Bcl-2, Bip, E-Cadherin, 
Claudin-1, Bax, Bad, 




Overexpression of miR-1 by targeting 
apoptotic pathways could increase the 
sensitivity of BCa cells to paclitaxel and 
cisplatin. 
[50] 
BCa Mouse/human; 21 pairs of 
BCa and adjacent normal 
tissue 
MDA-MB-231 EVI-1, E-cadherin, N- 
cadherin 
– miR-1 by down-regulating EVI-1 
expression could inhibit BCSCs 
proliferation and promote apoptosis. 
[58] 
BCa Mouse/human; 
139 pairs of BCa and adjacent 
normal tissue 
MCF-10A, MDA-MB- 
231, Hs578 T, MDA- 
MB-468 
Slug, AgO2 MALAT1 MALAT1 via the miR-1/slug axis could 
promote triple-negative breast cancer 
development. 
[59] 






– MALAT1 by competitively binding 
miR-1 with cdc42 could induce 
migration and invasion of human 










– Up-regulation of miR-1 by inducing cell 
apoptosis and the synergic inhibition of 
aggressive phenotypes could enhance 
the radiosensitivity of CRC cells. 
[57] 
CRC GEO database – – – miR-1-3p via multiple biological 
approaches could suppress CRC 
progression. 
[67] 
CRC 111 pairs of CRC and adjacent 
normal 
tissue 
HMrSV5, HCT-116, CL- 
187, ClonA1, HT-29, 
SW-620 
VEGF, VEGFR-2 – miR-1 by targeting VEGF could inhibit 
the progression of colon cancer. 
[68] 
CRC 28 pairs of CRC and ANTs – – – Downregulation of miR-1 expression 
could as a biomarker for CRC. 
[69] 
CRC Mouse HCT-116, SW480, 
SW620, HT-29, 
CaCO2, HEK293 
HIF-1, Smad3, HK2, 
MCT4 
– miR-1 via the Smad3/HIF-1 axis could 
regulate glucose metabolism and 
controlling tumorigenesis in CRC. 
[70] 
CRC Mouse/human; 
75 pairs of CRC and adjacent 
normal tissue 
LDL-1, WiDr, SW480, 
COLO21 
P62, LC3I, LC3II, 
PTBP1, PKM2, PKM1 
– PTBP1-associated miR-1 could induce 
growth inhibition through autophagy 
and overturn the Warburg effect in 
colorectal tumors. 
[71] 
Prostate cancer (PCa) 20 pairs of PCa and ANTs RWPE-1, C4-2, 22Rv1, 
LNCaP, PC3, 293 T 
CDK4 PCA3 LncRNA PCA3 via the miR-1/CDK4 axis 
could regulate glycolysis, viability, and 
apoptosis in PCa. 
[72] 
PCa 20 pairs of PCa and ANTs PC3, LNCap, DU145, 
RWPE-1, C4-2 
KRAS, caspase-3, BAX, 
bcl-2, PARP 
MALAT1 MALAT1 by up-regulating miR-1 and 
downregulating KRAS could suppress 
PCa. 
[73] 
PCa TCGA database – PAICS, CDH1, TWIST1, 
ZWINT, KIAA0101, 
SRC, AR 
– miR-1 could aid the clinical diagnosis 
of PCa. 
[74] 
PCa PCa recurrent group (n = 27); 
non-recurrent (n = 51) 
– – – Down-regulation of miR-1 could 
function as an important independent 
predicative factor for PCa recurrence. 
[75] 
PCa Mouse/human; 
32 pairs of PCa and ANTs 
DU145, PC3, LNCap, 
22Rv1, RasB1 
TWIST1 EGFR EGFR/miR-1 axis by activating TWIST1 
could promote PCa bone metastasis. 
[76] 
PCa 22RV1, LNcaP – [77] 
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Table 4 (continued ) 
Type of Cancer Samples Cell Lines Target Pathway Function Ref 
Mouse/human; 
124 pairs of PCa and ANTs 
E2F5, PFTK1, CDK2, 
CDK4 
miR-1-3p by repressing E2F5 and 
PFTK1 could modulate prostate cancer 
cell aggressiveness. 







MALAT1 Knockdown of MALAT1 by sponging 
miR-1‑3p could inhibit migration, 






Mouse/human; 8 pairs of 
ESCC and ANTs 




Fibronectin-1 Wnt, TGF- 
β, MAPK, 
p53 
Downregulation of miR-1 could 
suppress cell proliferation and 
migration and promotes ESCC cell 
apoptosis. 
[79] 
ESCC 74 pairs of ESCC and ANTs TE-1 PIK3CA, Akt, surviving Akt miR-1 by suppressing the PI3K3A/Akt/ 
survivin axis could enhance sensitivity 
to gefitinib and also inhibit 





38 pairs of NSCLC and ANTs A549, Calu1, H1299, 
H460, BEAS-2B 
ANXA2, CDK4, CDK6, 
CCND1 
RMRP RMRP/miR-1-3p axis by upregulating 
ANXA2 expression could promote cell 
proliferation and invasion in NSCLC. 
[60] 
NSCLC Plasma samples from NSCLC 
(n = 47) and normal group 
(n = 41) 
– – – The decrease of miR-1 expression in 
blood samples could help distinguish 
NSCLC patients from healthy subjects. 
[81] 
NSCLC Bronchoalveolar lavage cell 
(BAL) and sputum from 
NSCLC (n = 30) and cancer- 
free group (n = 30) 
– – – The decrease of miR-1 could be used for 
early detection of NSCLC. 
[82] 
Lung Cancer – A549, 95D SDF-1, CXCR4, Bcl-xL, 
NF-kB 
– Regulation of miR-1 on SDF-1 
biogenesis in cancer-associated 
fibroblasts could increase tumor 
progression, metastasis, and resistance 
to therapy via paracrine. 
[83] 
Bladder Cancer (BLC) 48 pairs of BLC and ANTs EJ, J82, T24, UM-UC- 
3, SV-HUC-1 
Glutaminase – miR-1-3p by targeting the glutaminase 
could inhibit the proliferation, 
migration, and invasion of BLC cells. 
[84] 
BLC BLC (n = 18), normal samples 
(n = 6) 
5637, T24, UM-UC-3 CCL2 – miR-1-3p by targeting CCL2 could 
suppress proliferation and invasion of 
BLC cells. 
[85] 
BLC 34 pairs of BCL and ANTs SV-HUC-1, 5637, T24, 
J82, UM-UC-3 
SFRP1 – miR-1-3p by targeting SFRP1 could 
suppress the proliferation, invasion, 
and migration of BCL cells. 
[86] 
BLC Bladder transitional cell 
carcinoma (TCC) (n = 43); 
normal bladder transitional 
cell (NBTC) (n = 36) 
TCC J82, T24, SV- 
HUC-1, HEK293 T 
HuR, E-Cadherin, 
vimentin, caspase-3, 
PARP, Bcl-2, Bax, 
HOTAIR miR-1 via HuR/HOTAIR axis could 
inhibit cell proliferation, migration, 
invasion, and promoted cell apoptosis 
in BCL. 
[87] 
Osteosarcoma (OS) Dog – MET, MCL-1 – The decrease of miR-1 expression 
associated with higher MET expression 
could be used as a biomarker for canine 
OS treatment. 
[88] 
OS 34 pairs of OS 
and adjacent normal tissues 
SAOS-2, U2OS, NHOst VEGFA – miR-1 by targeting VEGFA could 
inhibit cell growth, migration, and 
invasion in OS Cells. 
[89] 
OS Mouse/human; 
OS (n = 41), normal bone 
tissue (n = 12) 
MG-63, U-2OS c-MET – EGCG via regulating miR-1/c-MET 
interaction could suppress OS cell 
growth. 
[90] 
OS Mouse MG63, Saos2, G292, 
hFOB1.19 
PAX3, p21, p53, p73 – miR-1 could induce arrest in the G0/G1 
phase and suppress cell proliferation in 
OS. 
[91] 
Oral Squamous Cell 
Carcinomas (OSCC) 
OSCC (n = 381), normal 
tissue (n = 35) 
SAS, GNM, Fadu, 
HSC3, SCC4, 
OECM-1, Ca9-22, OC3, 
NHOK 
Slug, E-cadherin – miR-1 by targeting the Slug could 
enhance tumorigenicity and 
invasiveness in OSCC. 
[92] 
Head & Neck 
Squamous Cell 
Carcinoma (HNSCC) 
22 pairs of HNSCC and 
adjacent normal epithelial 
FaDu, SAS, HSC3 EGFR, c-MET, AKT, 
Erk1/2 
MAPK Down-regulation of miR-1by targeting 
EGFR and c-MET could enhance cancer 





43 pairs of PDAC and ANTs – – – Abnormal alterations of miR-1 in PDAC 
could determine the prognosis of 
patients with PDAC by noninvasive 
methods. 
[94] 
GC and BCa Mouse MGC-803, MKN45, 
MKN74, AGS, GES-1, 
HGC-27, A375, CCC- 
ESF, 
MCF-7 
CDK4, TWF1, WASF2, 
CNN3, CORO1C, 
TMSB4X 
– miR-1 by down-regulating target genes 
expression could inhibit tumor growth 
and metastasis of breast and gastric 
cancers. 
[95] 
Mesothelioma – CRL-2081, CRL-5820, 
CRL-5826, 
CRL-5915, CRL-5946, 
PIM-1 – miR-1 by down-regulation of 
PIM1could partake in cell proliferation, 
invasion, and migration in 
mesothelioma. 
[96] 
(continued on next page) 
A. Safa et al.                                                                                                                                                                                                                                     
Biomedicine & Pharmacotherapy 132 (2020) 110903
8
Table 4 provides a summary of the results of researches which gauged 
the tumor suppressor role of miR-1. 
6. Discussion 
Numerous lines of evidence have shown the important roles of 
miRNAs in the developmental processes. These transcripts can regulate 
expression of several targets at the post-transcriptional phase. Accord-
ingly, they are involved in the pathogenesis of diverse human disorders. 
miR-1 has a particular situation in this regard. While initial studies 
indicated its specific expression in muscle tissues, additional in-
vestigations demonstrated its widespread expression in different tissues 
including dental epithelial cells and hepatocytes. The diverse function of 
miRNAs in the physiological and pathological events can be explained 
by its diverse targets. This miRNA has been shown to target several 
genes including HSP60, KLF4, HAND2, Srsf9, Pax7, HDAC4 and TLR1. 
Notably, the seed sequence of miR-1 is the same as another miRNA, 
namely miR-206 [8], indicating similar targets for these miRNAs. Most 
notably, miR-1 has functional interactions with some long non-coding 
RNAs (lncRNAs) namely HOTAIR, MALAT1, UCA1 and H19, more 
emphasizing on consideration of the functional networks between 
different kinds of transcripts. Construction of TF/miR-1/lncRNA net-
works using the available high throughput data would facilitate iden-
tification of the role of this miRNA in diverse pathological and 
physiological processes. It is worth mentioning that such functional 
networks might have tissue-specific roles. 
miR-1 has been regarded as a tumor suppressor gene in various tis-
sues. Such effects have been exerted through modulation of a number of 
oncogenes such as Bcl-2. In addition to its roles in suppression of cancer, 
its levels have been shown to foresee the occurrence of some side effects 
of anti-cancer drugs. For instance, doxorubicin-induced cardiotoxicity 
can be predicted by assessment of circulating levels of miR-1 [102]. 
Levels of this miRNA can also be used as diagnostic/prognostic bio-
markers for a range of disorders including cancer [54], and adverse 
outcomes of MI [25]. Moreover, miR-1 expression in heart tissue had the 
appropriate accuracy in differentiation of patients with AMI from sud-
den cardiac death [33]. 
miR-1 can be regarded as a target for manipulation of inflammatory 
processes. This miRNA has a prominent role in inhibition of KLF4 and 
induction of NF-κB [18]. NF-κB has been shown to activate expression of 
several pro-inflammatory proteins such as cytokines and chemokines, 
thus contributing in the control of inflammasome. Moreover, this 
nuclear factor regulates survival, function and differentiation of several 
immune cells. Therefore, NF-κB is involved in the pathogenesis of 
numerous inflammatory conditions [103]. Since dysregulation of miR-1 
can partake in the pathogenesis of inflammatory conditions, this miRNA 
might serve as a therapeutic targets in these disorders. In addition, Klf4 
up-regulation is involved in the activation of epithelial cytokines and 
consequent development of esophageal squamous cell carcinoma in 
animal models [104]. Thus, miR-1-mediated regulation of KLF4 might 
be important in the carcinogenic processes as well. Another layer of 
regulatory role of miR-1 on NF-κB in the context of cancer has been 
represented by the effects of this miRNA on the expression of SDF-1 and 
SDF-1-mediated enhancement of cancer cell proliferation and chemo-
resistance through involvement of NF-κB [83]. 
Modulation of expression of this miRNA might be regarded as a 
therapeutic option in some disorders. For instance, intravenous injection 
of antagomiR-1 following middle cerebral artery occlusion has been 
shown to ameliorate neurological impairment and decrease infarction 
size, brain edema, and blood-brain barrier permeability [105]. More-
over, metformin has been shown to amend cardiac conduction defect 
through modulation of expression of miR-1 [21]. Besides, Astragalus 
Root dry extract has been demonstrated to inhibit arrhythmia and pre-
serve CVB3-induced Cx43 expression by influencing expression of miR-1 
[26]. 
Taken together, miR-1 has diverse roles in the developmental pro-
cesses and is involved in the development of diverse disorders particu-
larly MI and cancer. In addition, it has been considered as a potential 
marker and therapeutic target in these conditions. Further in vivo 
investigation of miR-1-targetted therapeutic modalities would facilitate 
translation of this wealth of basic science data into clinical application. 
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Table 4 (continued ) 
Type of Cancer Samples Cell Lines Target Pathway Function Ref 
ACC-Meso-1, ACC- 
Meso-4, NPL 
Cervical Cancer (CC) Mouse/Human;57 pairs of CC 




G6PD – miR-1 by targeting G6PD could 
suppress the development and 
progression of high-risk papilloma 





NPC (n = 26), non-NPC 
(n = 18) 
5− 8 F, CNE-2, HONE- 
1, SUNE-1, NPE 
Slug, Bcl-2, Caspase-3 MALAT1 MALAT1 by modulating miR-1/slug 
axis could regulate radioresistance in 
NPC. 
[61] 
Clear Cell Renal Cell 
Carcinoma (Ccrcc) 
41 pairs of ccRCC and ANTs HK-2, ACHN, 786-o, 
SN12PM6, CAKl-1, OS- 
RC-2 
CDK4, CDK6, Caprin1, 
Slug, β-Tubulin, N- 
cadherin, Vimentin, E- 
cadherin, Rb 
– The decrease of miR-1 expression could 
inhibit ccRCC cell proliferation and 
interferes with cell cycle regulation and 
metastasis. 
[98] 
Renal Cell Cancer 
(RCC) 
Mouse/human; 58 pairs of 
RCC and ANTs 
HK-2, OS-RC-2, CAKI- 




– Overexpression of miR-1-3p by 
reducing fibronectin-1 could inhibit 
EMT in RCC. 
[99] 
Thyroid Cancer (TC) 26 pairs of TC 
and adjacent normal tissues 
Nthy-ori 3-1, TPC-1, 
FTC-133, B-CPAP, 
SW579 
CCND2 HOTAIR HOTAIR via miR-1/CCND2 axis could 
promote the development and 
progression of TC. 
[100] 




– Overexpression of miR-1 by targeting 
the MINOS1/GPD2 axis could mediate 
mitochondria damage in cancer stem 
cells. 
[101]  
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